A detailed history of Wellington Management Group LLP transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 5,814,446 shares of MORF stock, worth $331 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,814,446
Previous 4,022,984 44.53%
Holding current value
$331 Million
Previous $142 Million 39.89%
% of portfolio
0.04%
Previous 0.03%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$26.12 - $34.07 $46.8 Million - $61 Million
1,791,462 Added 44.53%
5,814,446 $198 Million
Q1 2024

May 15, 2024

BUY
$26.64 - $40.31 $107 Million - $162 Million
4,022,984 New
4,022,984 $142 Million
Q4 2023

Feb 12, 2024

BUY
$19.95 - $31.0 $67.4 Million - $105 Million
3,377,310 New
3,377,310 $97.5 Million
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $23.8 Million - $66.4 Million
1,117,985 Added 48.53%
3,421,820 $78.4 Million
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $41.2 Million - $74.6 Million
1,200,911 Added 108.88%
2,303,835 $132 Million
Q1 2023

May 12, 2023

SELL
$26.01 - $48.69 $7.97 Million - $14.9 Million
-306,589 Reduced 21.75%
1,102,924 $41.5 Million
Q4 2022

Feb 13, 2023

BUY
$24.14 - $30.37 $1.6 Million - $2.02 Million
66,378 Added 4.94%
1,409,513 $37.7 Million
Q3 2022

Nov 14, 2022

SELL
$22.23 - $33.37 $8.18 Million - $12.3 Million
-368,074 Reduced 21.51%
1,343,135 $38 Million
Q2 2022

Aug 15, 2022

BUY
$19.74 - $43.01 $25.4 Million - $55.4 Million
1,289,063 Added 305.36%
1,711,209 $37.1 Million
Q1 2022

May 16, 2022

BUY
$36.25 - $52.02 $15.3 Million - $22 Million
422,146 New
422,146 $16.9 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.